Cardioprotection with Yet Another SGLT2 Inhibitor - An Embarrassment of Riches

Affiliations

¹ From the Department of Medicine, University of Arizona, Tucson (F.C.B.); the Department of Internal Medicine, University of Michigan, Ann Arbor (F.C.B.); and the Institute of Health and Society, University of Oslo, and the Department of Medicine, Lovisenberg Diaconal Hospital, Oslo (P.O.V.).

Editorial

Frank C Brosius et al. N Engl J Med. 2021.

. 2021 Jan 14;384(2):179-181.

doi: 10.1056/NEJMe2033176.

¹ From the Department of Medicine, University of Arizona, Tucson (F.C.B.); the Department of Internal Medicine, University of Michigan, Ann Arbor (F.C.B.); and the Institute of Health and Society, University of Oslo, and the Department of Medicine, Lovisenberg Diaconal Hospital, Oslo (P.O.V.).

No abstract available

Comment on

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200892 Clinical Trial.